LitAlert ~~ GeneLit.com

    • Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    • Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • Breast Cancer Res. 2022 Nov 18;24(1):80. doi: 10.1186/s13058-022-01572-6.

    • Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
    • Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
    • Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.

    • Impact of totally implanted venous access port placement on body image in women with breast cancer.
    • Pizzuti G, Cassani C, Bottazzi A, Ruggieri A, Della Valle A, Dionigi F, Anghelone CAP, Sgarella A, Ferrari A.
    • J Vasc Access. 2022 Nov 18:11297298221136330. doi: 10.1177/11297298221136330. Epub ahead of print.

    • FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer.
    • Harris J.
    • OncLive. 2022 Nov 18.

    • Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
    • Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H.
    • Expert Opin Pharmacother. 2022 Nov 17. doi: 10.1080/14656566.2022.2149322. Epub ahead of print.
    • Review

    • Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7,500 BRCA variants derived from Asian population.
    • Qin Z, Li J, Tam B, Sinha S, Zhao B, Bhaskaran SP, Huang T, Wu X, Chian JS, Guo M, Kou SH, Lei H, Zhang L, Wang X, Lagniton PNP, Xiao F, Jiang X, Wang SM.
    • Int J Cancer. 2022 Nov 17. doi: 10.1002/ijc.34359. Epub ahead of print.

    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    Related:

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    • Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5228. Epub ahead of print.

    •• Identifier: NCT03330405: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    • Blood Test Signals BRCA Breast Cancer 2 Years Before Diagnosis.
    • Davenport L.
    • Medscape. 2022 Nov 17.

    • Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.
    • Badheeb M, Abdelrahim A, Esmail A, Umoru G, Abboud K, Al-Najjar E, Rasheed G, Alkhulaifawin M, Abudayyeh A, Abdelrahim M.
    • Curr Oncol. 2022 Nov 15;29(11):8693-8719. doi: 10.3390/curroncol29110686.

    • Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    • Rémond MS, Pellat A, Brezault C, Dhooge M, Coriat R.
    • ESMO Open. 2022 Nov 15;7(6):100638. doi: 10.1016/j.esmoop.2022.100638. Epub ahead of print.

    • BRCA2 gene mutation in cancer.
    • Xie C, Luo J, He Y, Jiang L, Zhong L, Shi Y.
    • Medicine (Baltimore). 2022 Nov 11;101(45):e31705. doi: 10.1097/MD.0000000000031705.

    • Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants.
    • Shah I, Silva-Santisteban A, Germansky KA, Kandasamy C, Mlabasati J, Huang DC, Wadhwa V, Bilal M, Sawhney MS.
    • Pancreas. 2022 Aug 1;51(7):733-738. doi: 10.1097/MPA.0000000000002104.